HomeNewsBusinessMarketsSensex, Nifty extend losing streak to 3rd session; financials drag; mid-, small-caps rise over 1%

Sensex, Nifty extend losing streak to 3rd session; financials drag; mid-, small-caps rise over 1%

Concerns over sluggish earnings growth, premium valuations, and uncertainty surrounding U.S. trade policies fueled the sell-off.

February 20, 2025 / 15:39 IST
Story continues below Advertisement
Mid and small-caps outperformed the benchmarks with the BSE Midcap and the BSE Smallcap index advancing over 1 percent each.
Mid and small-caps outperformed the benchmarks with the BSE Midcap and the BSE Smallcap index advancing over 1 percent each.

India's benchmark indices, Sensex and Nifty, ended marginally lower for the third session on February 20, dragged lower by financial stocks as global trade tensions weighed on investor sentiment. Concerns over sluggish earnings growth, premium valuations, and uncertainty surrounding U.S. trade policies fueled the sell-off.

At close, the Sensex was down 222 points or 0.3 percent at 75,716, while the Nifty slipped 26 points, or 0.1 percent to 22,906. On the NSE, 1,861 stocks advanced while 727 declined. So far in 2025, Indian equities have shed over 3 percent and are down nearly 13 percent from their record highs in late September.

Story continues below Advertisement

The session opened in the red, mirroring weakness across Asian markets, as investors braced for the inflationary effects of fresh U.S. tariff measures. On February 19, Trump announced plans to impose tariffs of 25 percent or more on auto, pharmaceutical, and semiconductor imports. While South Korea and Japan are among the most exposed in auto exports, India’s extensive pharmaceutical trade with the U.S. faces potential headwinds.

"The result season is behind us, so any volatility caused by earnings announcements has settled. Additionally, most of Trump's policy announcements have already been factored into the market. There are no new triggers or concerns that could significantly impact sentiment," said Amish Shah, Research Analyst at Taurus Corporate Advisory Services.